CAGLUEN 60mg tablets medication leaflet

B01AF03 edoxaban • Blood and blood forming organs | Antithrombotic agents | Direct factor xa inhibitors

Edoxaban is an oral anticoagulant from the class of direct factor Xa inhibitors, used for the prevention and treatment of thrombosis and embolism. It works by inhibiting the activity of factor Xa, an enzyme essential for blood clotting, thereby preventing the formation of blood clots.

It is indicated for:

- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Prevention of recurrence of these conditions.

Edoxaban is taken orally, once daily, with the dose adjusted based on the patient's weight, kidney function, and concomitant medications.

Side effects may include bleeding (nasal, gastrointestinal, or other types), anemia, nausea, skin rashes, or, rarely, severe allergic reactions. Patients should be monitored for signs of excessive bleeding.

Edoxaban is contraindicated in patients with active bleeding, severe liver impairment, severe coagulopathies, or those taking other anticoagulants. It is important to use it as prescribed by a doctor, and discontinuation should be done cautiously to avoid the risk of thrombosis.

General data about CAGLUEN 60mg

Substance: edoxaban

Date of last drug list: 01-02-2025

Commercial code: W70858003

Concentration: 60mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHAROS MT LTD. - MALTA

Holder: VIATRIS LIMITED - IRLANDA

Number: 15774/2025/03

Shelf life: 2 years

Concentrations available for edoxaban

15mg, 30mg, 60mg

Other substances similar to edoxaban